Rocket Pharmaceuticals, Inc.
RCKT
$7.88
$0.192.47%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 36.70% | 45.86% | 57.52% | 39.97% | 16.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.01% | 6.11% | 7.21% | 8.33% | -7.80% |
| Operating Income | -4.01% | -6.11% | -7.21% | -8.33% | 7.80% |
| Income Before Tax | -1.12% | -7.79% | -6.00% | -6.38% | 10.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.12% | -7.79% | -6.00% | -6.38% | 10.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.12% | -7.79% | -6.00% | -6.38% | 10.59% |
| EBIT | -4.01% | -6.11% | -7.21% | -8.33% | 7.80% |
| EBITDA | -3.41% | -5.29% | -6.44% | -7.60% | 8.27% |
| EPS Basic | 3.24% | 5.41% | 9.00% | 9.66% | 30.17% |
| Normalized Basic EPS | 1.72% | 6.24% | 9.75% | 9.40% | 27.56% |
| EPS Diluted | 3.24% | 5.41% | 9.00% | 9.66% | 30.17% |
| Normalized Diluted EPS | 1.72% | 6.24% | 9.75% | 9.40% | 27.56% |
| Average Basic Shares Outstanding | 4.49% | 13.94% | 16.49% | 17.74% | 28.05% |
| Average Diluted Shares Outstanding | 4.49% | 13.94% | 16.49% | 17.74% | 28.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
